AFIB:NSD-Acutus Medical Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 0.88

Change

-0.03 (-3.19)%

Market Cap

USD 0.03B

Volume

0.05M

Avg Analyst Target

USD 1.83 (+108.33%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AFIB Stock Forecast & Price:
Based on the Acutus Medical Inc stock forecasts from 2 analysts, the average analyst target price for Acutus Medical Inc is USD 1.83 over the next 12 months. Acutus Medical Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Acutus Medical Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Acutus Medical Inc’s stock price was USD 0.88. Acutus Medical Inc’s stock price has changed by +0.92% over the past week, -27.87% over the past month and -90.05% over the last year.

About Acutus Medical Inc (AFIB:NSD)

Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-1.56 (-1.90%)

USD32.46B 198.40 79.66
ALGN Align Technology Inc

-3.90 (-1.85%)

USD16.57B 26.65 16.84
PODD Insulet Corporation

-1.78 (-0.77%)

USD16.39B 472.28 113.28
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD ABIOMED Inc

-3.30 (-1.33%)

USD11.46B 53.61 36.83
SWAV Shockwave Medical Inc

+2.23 (+0.81%)

USD9.83B 188.63 145.48
BRKR Bruker Corporation

+0.22 (+0.42%)

USD7.25B 27.18 15.48
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67
NARI Inari Medical Inc

-1.32 (-1.78%)

USD3.77B N/A -490.66
IRTC iRhythm Technologies Inc

-0.41 (-0.33%)

USD3.71B N/A -31.65

ETFs Containing AFIB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -74.19% 14% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.19% 14% F 15% F
Trailing 12 Months  
Capital Gain -90.16% 3% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -90.16% 3% F 7% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -44.78% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.78% 3% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 43.17% 58% F 32% F
Risk Adjusted Return -103.74% 6% F 2% F
Market Capitalization 0.03B 25% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.34 97% A+ 95% A
Price / Cash Flow Ratio -0.27 30% F 42% F
EV/EBITDA 0.30 27% F 46% F
Management Effectiveness  
Return on Equity -123.37% 24% F 13% F
Return on Invested Capital -71.93% 26% F 19% F
Return on Assets -52.56% 18% F 7% F
Debt to Equity Ratio 38.23% 47% F 45% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.09 38% F 30% F
Short Percent 3.69% 44% F 38% F
Beta 1.09 58% F 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.